Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Interest & Investment Income: 2021-2024

  • Pharming Group N.V's Interest & Investment Income was N/A to $2.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.2 million, marking a year-over-year change of. This contributed to the annual value of $799,000 for FY2023, which is N/A change from last year.
  • Per Pharming Group N.V's latest filing, its Interest & Investment Income stood at $2.7 million for Q4 2024, which was down 0.00% from $2.7 million recorded in Q2 2024.
  • In the past 5 years, Pharming Group N.V's Interest & Investment Income registered a high of $2.7 million during Q2 2024, and its lowest value of $43,000 during Q2 2021.
  • Moreover, its 2-year median value for Interest & Investment Income was $2.7 million (2024), whereas its average is $2.1 million.
  • Data for Pharming Group N.V's Interest & Investment Income shows a peak YoY spiked of 237.80% (in 2024) over the last 5 years.
  • Over the past 3 years, Pharming Group N.V's Interest & Investment Income (Quarterly) stood at $43,000 in 2021, then reached $799,000 in 2023, then spiked by 237.80% to $2.7 million in 2024.
  • Its Interest & Investment Income stands at $2.7 million for Q4 2024, versus $2.7 million for Q2 2024 and $799,000 for Q2 2023.